Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Studying the function of liver cancer genes in mini-organs

Researchers have developed a human model in which they use organoids, or mini organs, to study the function of specific genes that are mutated in liver cancer.

Using this method, they have found that mutations in BAP1, a gene commonly mutated in liver cancer, changes the behaviour of the cells, which may make them more likely to be invasive.

Their results have been published in the scientific journal Cell Stem Cell.

Organoids and cancer research

Organoids are mini organs that can be grown in the lab, from a very small piece of tissue derived from a variety of organs.

They have been used in cancer research for a few years, mainly by comparing organoids derived from healthy organs to those derived from tumours.

This approach however is not suitable to investigate the function and the role of specific genes that are already known to be mutated in cancer.

In order to learn more about tumour formation, there was a need for a clean model in which organoids with and without such mutations can be compared.

New model

The researchers developed a new model in which organoids from the healthy human liver are genetically altered using molecular scissors called CRISPR/Cas9, to study the function of the genetic alteration in tumour formation.

"Studying the function of such mutations in tumour formation is especially important in liver cancer," said Benedetta Artegiani, one of the researchers. "Since it is a very heterogeneous type of cancer: a wide variety of mutations in different genes are found in different patients."

Until now, the function of many of these genes in tumour development remains unknown.

The newly developed model therefore is a valuable tool to address the function of specific genes in liver cancer formation.

BAP1

The model was exploited to shed light on the function of BAP1, a gene that is mutated in approximately 15-20 percent of liver cancer patients and of which the specific role in liver tumour development so far remained unknown.

The researchers found that organoids in which BAP1 was mutated had very different characteristics compared to the healthy organoids: they turned into solid masses that grew faster, were more motile and fused with other organoids.

These observations resemble the characteristics of a more invasive malignant tumour.

Furthermore, these changes in organoid morphology and behaviour can be reversed by adding normal BAP1 to the organoids.

In addition, the researchers made organoids with mutations in four genes that are often mutated in liver cancer, and organoids in which a mutation in BAP1 was added.

They found that while the organoids in which the four common liver cancer genes were mutated only formed benign adenoma when transplanted into mice, the organoids in which BAP1 was also mutated formed malignant tumours - the so-called cholangiocarcinoma.

Choosing the right model

By combining different approaches - microscopy, time-lapse imaging and "multi-omics" (RNA, DNA and protein-based) techniques, the researchers dug into the mechanisms through which a mutation in BAP1 can affect tumour development.

They found that mutating BAP1 changes which genes are active in the organoids and that these changes in gene activity can be reversed.

"These changes may depend on the cell type in which BAP1 is mutated," said Artegiani. "Which may explain why the previously described functions of BAP1 differ between different types of cells. This underlines the importance of studying gene function in a relevant model, derived from the organ and the organism of interest."

Tumour modeling

The researchers show mutations in BAP1 are important for the transition from a benign to a malignant liver tumour.

Furthermore, they show that their model can be used to model liver tumours by mutating single genes.

Since the model makes it relatively straightforward to manipulate healthy human organoids with CRISPR/Cas9, it may be used to study the function of the many genes with unknown function in liver cancer, both individually and together, to look at the combined effect of different mutations.

This will provide more insight into the development of liver tumours.

Source: Hubrecht Institute

Image credit: Benedetta Artegiani / © Hubrecht Institute

0

Comments

Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation